Eagle Pharmaceuticals, Inc. (EGRX) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On November11, 2016, Eagle Pharmaceuticals,Inc., or the Company,
presented the attached discussion of the Companys business model,
products, and product candidates at the Companys previously
announced 2016 Investor Day in New York, New York.

A copy of the above referenced presentation is furnished as
Exhibit99.1 to this Current Report on Form8-K. The information
furnished to Item 7.01 of this current report, including
Exhibit99.1, shall not be deemed to be filed for the purposes of
Section18 of the Securities Exchange Act of 1934, as amended. As
such, this information shall not be incorporated by reference
into any of the Companys reports or other filings made with the
Securities and Exchange Commission. The furnishing of the
information in this current report is not intended to, and does
not, constitute a determination or admission by the Company that
the information in this current report is material or complete,
or that investors should consider this information before making
an investment decision with respect to any security of the
Company.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits

About Eagle Pharmaceuticals, Inc. (EGRX)